[Treatment of bilateral spontaneous pneumothorax during pazopanib therapy for pulmonary soft tissue sarcoma metastases. What to do when there is so few evidence?]

Date publication

octobre 2016

Journal

Revue de pneumologie clinique

Auteurs

Membres identifiés du Cancéropôle Est :
Dr RIOS Maria

Tous les auteurs :
Agrafiotis AC, Prieto M, Verhaeghe JL, Siat J, Grosdidier G, Rios M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27561973

Résumé

Soft tissue sarcomas are rare malignant tumors with a great variety of histological types and different response to multimodality treatment. Pazopanib has been recently introduced for the treatment of non-adipocytic metastatic soft tissue sarcomas which are resistant to conventional chemotherapy. Spontaneous pneumothorax is a rare but well recognized complication of this molecule and its treatment is quite challenging. The case reported herein describes the surgical management of a simultaneous bilateral spontaneous pneumothorax in a patient with pulmonary metastases treated with pazopanib. It underlines the fact that the main objective should be the maintenance of the treatment in patients who benefit from it. Close oncologic and surgical collaboration is crucial in order to deal with adverse effects due to the anti-angiogenic action of pazopanib.

Référence

Rev Pneumol Clin. 2016 Oct;72(5):293-295